Metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common and progressive liver condition driven by metabolic risk factors such as obesity and type 2 diabetes. It begins with the accumulation of fat in the liver (steatosis) and can progress to metabolic dysfunction-associated steatohepatitis (MASH), a more severe stage marked by inflammation and liver cell damage. If left untreated, MASH can lead to fibrosis, cirrhosis, liver failure, or even liver cancer. Despite its rising global prevalence, effective therapeutic options remain limited, making MASLD one of the most urgent unmet needs in modern medicine.